Krajina: Írsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
Anti-d immunoglobulin
Octapharma (IP) SPRL
J06BB; J06BB01
Anti-d immunoglobulin
625 international unit(s)/millilitre
Solution for injection
Product subject to prescription which may not be renewed (A)
Specific immunoglobulins; anti-D (rh) immunoglobulin
Not marketed
2006-04-28
_20210311_pil_870_IE_15.14_en _ _1/6 _ PACKAGE LEAFLET: INFORMATION FOR THE USER RHESONATIV 625 IU/ML, SOLUTION FOR INJECTION Human anti-D immunoglobulin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Rhesonativ is and what it is used for 2. What you need to know before you use Rhesonativ 3. How to use Rhesonativ 4. Possible side effects 5. How to store Rhesonativ 6. Contents of the pack and other information 1 WHAT RHESONATIV IS AND WHAT IT IS USED FOR Rhesonativ is an immunoglobulin and contains antibodies to the Rhesus factor. If a woman who lacks the Rhesus factor in her red blood cells (=Rh-negative) is pregnant with an unborn baby which has the Rhesus factor (=Rh-positive), her immune defence system may be stimulated to form antibodies to the Rhesus factor. These antibodies may harm her unborn baby, especially in subsequent pregnancies. Rhesonativ is used to keep the Rh-negative woman from becoming immunised in the course of pregnancy and childbirth, and in this way prevent harm to the unborn baby. Rhesonativ is used in Rh-negative woman in case of: Anti-D prevention therapy for pregnant women who are Rh- negative Delivery of a Rh-positive baby Abortion/threatened abortion (miscarriage/threatened miscarriage) Pregnancy outside the uterus, certain growths inside the uterus (mole), or bleeding of blood of the unborn baby into the normally separated maternal circulation or death of the unborn baby late in pregnancy Invasive procedures during pregnancy such Prečítajte si celý dokument
Health Products Regulatory Authority 09 June 2021 CRN00C137 Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Rhesonativ 625 IU/ml, solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human anti-D immunoglobulin. 1 ml contains: Human anti-D immunoglobulin 625 IU (125 micrograms) Human protein content: 165 mg there of immunoglobulin G, at least 95% The content of IgA does not exceed 0.05% of the total protein content. One ampoule of 1 ml contains 625 IU (125 micrograms) of human anti-D immunoglobulin. One ampoule of 2 ml contains 1250 IU (250 micrograms) of human anti-D immunoglobulin. The potency is determined using the European Pharmacopoeia assay. The equivalence in International Units of the International Reference Preparation is stated by the World Health Organization. Distribution of the IgG subclasses (approx. values): IgG1 ............. 70.5% IgG2 ............. 26.0% IgG3 ............. 2.8% IgG4 ............. 0,8% The maximum IgA content is 82.5 micrograms/ml. Produced from the plasma of human donors. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. The colour of the solution can vary from colourless to pale-yellow up to light brown. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS PREVENTION OF RH(D) IMMUNISATION IN RH(D) NEGATIVE CHILDBEARING AGE WOMEN. ANTENATAL PROPHYLAXIS o Planned antenatal prophylaxis o Antenatal prophylaxis following complications of pregnancy including Abortion/threatened abortion, ectopic pregnancy or hydatidiform mole, intrauterine fetal death (IUFD), transplacental haemorrhage (TPH) resulting from ante-partum haemorrhage (APH), amniocentesis, chorionic biopsy, obstetric manipulative procedures, e.g. external version, invasive interventions, cordocentesis, blunt abdominal trauma or fetal therapeutic intervention. POSTNATAL PROPHYLAXIS Health Products Regulatory Authority 09 June 2021 CRN00C137 Page 2 of 8 o Delivery of a Rh(D) positive (D, D weak , D partial ) baby TREATMENT OF RH Prečítajte si celý dokument